PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies ...
Morning Overview on MSN
Study: RNA drugs work best when they reshape RNA, not just bind to it
Researchers led by Davide Incarnato at the University of Groningen have demonstrated that the FDA-approved cancer drug ...
A new study from the Italian Institute of Technology (IIT), in collaboration with Uppsala University (Sweden) and AstraZeneca ...
PepGen shared results of a trial of patients with myotonic dystrophy type 1, a disorder that causes muscle weakness. The trial measured improvements in restoring normal RNA splici ...
Discusses Topline Results From Lowest Dose MAD Cohort in Phase II FREEDOM2 Study With Favorable Safety, Splicing and vHOT Data March ...
Tuberculosis (TB) remains one of the world's most serious public health threats, with approximately one-quarter of the global ...
Johns Hopkins researchers have developed a powerful new AI tool called Splam that can identify where splicing occurs in genes—an advance that could help scientists analyze genetic data with greater ...
PepGen’s lead candidate for myotonic dystrophy type 1 barely beat the placebo in a Phase 2 trial in terms of fixing incorrect ...
A collaborative study published today in the journal Cell Reports provides evidence for a new molecular cause for neurodegeneration in Alzheimer’s disease. The study, led by researchers at Baylor ...
A wide spectrum of cancer-associated genetic alterations, including those that result in changes to the splicing of pre–messenger RNA (mRNA), can lead to the presentation of aberrant peptides as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results